Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Kantoff

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Cold Spring Harbor Symposia on Quantitative Biology|January 1, 1986
Gene transfer and expression in nonhuman primates using retroviral vectorsW F Anderson, P Kantoff, M Eglitis, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The epidemic of prostate cancer and the medical literature: a causal association?E Giovannucci, P Kantoff, D Spiegelman, et al.
Cancer Research|April 6, 2001
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B studyR A Bok, S Halabi, D T Fei, et al.
Journal of the National Cancer Institute|December 7, 2000
Her-2-neu expression and progression toward androgen independence in human prostate cancerS Signoretti, R Montironi, J Manola, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2001
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemiaX F Yang, C J Wu, S McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancerW Xie, P Ravi, M Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancerW K Kelly, T Curley, S Slovin, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Prostate CancerR R Bahnson, G E Hanks, R P Huben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Cold Spring Harbor Symposia on Quantitative Biology|January 1, 1986
Gene transfer and expression in nonhuman primates using retroviral vectorsW F Anderson, P Kantoff, M Eglitis, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The epidemic of prostate cancer and the medical literature: a causal association?E Giovannucci, P Kantoff, D Spiegelman, et al.
Cancer Research|April 6, 2001
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B studyR A Bok, S Halabi, D T Fei, et al.
Journal of the National Cancer Institute|December 7, 2000
Her-2-neu expression and progression toward androgen independence in human prostate cancerS Signoretti, R Montironi, J Manola, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 21, 2001
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemiaX F Yang, C J Wu, S McLaughlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2023
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancerW Xie, P Ravi, M Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancerW K Kelly, T Curley, S Slovin, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Prostate CancerR R Bahnson, G E Hanks, R P Huben, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
Pageof 3